U.S. spending on prescription drugs grew just barely in 2011, according to the annual report from IMS Health, which keeps track of these things.
But the reason for the barely discernible increase of 0.5 percent, to $320 billion, was not the expected one.
Normally, a slowdown in spending is because the drug industry hasn't produced many breakthrough medications — with their hefty price tags. But that wasn't the case this time around. Last year saw "the introduction of the most new medicines in a decade," according to the report, including "breakthrough therapies ... to treat several types of cancer, multiple sclerosis, hepatitis C and cardiovascular conditions."
Read the full story: http://hcp.lv/I0btZk
Source: NPR
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen